DS-1001B OPTIONS

quinupristin/dalfopristin will enhance the degree or effect of avanafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. CYP3A4 inhibitors might decrease avanafil clearance increasing systemic publicity to avanafil; enhanced ranges may bring about greater linked adverse activities; the most encouraged dose of S